SCHEMBL2249559

SCHEMBL2249559

CC(=O)Nc1ccc(OP(=O)(Oc2ccc(NC(C)=O)cc2)C(Cc2ccc(N(C(=O)OC(C)(C)C)C(N)=NC(=O)OC(C)(C)C)cc2)NS(C)(=O)=O)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLAU P00749 15/20 0.62
PLAT P00750 14/20 0.62
PLG P00747 13/20 0.62
F2 P00734 12/20 0.62
F10 P00742 5/20 0.46
NR3C1 P04150 1/20 0.34
KLK8 O60259 1/20 0.32
KLK2 P20151 1/20 0.32
KLK4 Q9Y5K2 1/20 0.32
ITGB3 P05106 1/20 0.32
ITGB1 P05556 1/20 0.32
ITGAV P06756 1/20 0.32
ITGA2B P08514 1/20 0.32
ITGB5 P18084 1/20 0.32
CNR2 P34972 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C8 P10632 1/20 0.31
CYP2C9 P11712 1/20 0.31
NPR3 P17342 1/20 0.31
CYP2C19 P33261 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16143958 0.89 PLAU (0.61) PLAUPLATPLGF2F10
SCHEMBL2358700 0.87 PLAU (0.46) PLAUPLATPLGF2F10
SCHEMBL2246863 0.86 PLAU (0.65) PLAUPLATPLGF2F10
SCHEMBL2249555 0.84 PLAU (0.56) PLAUPLATPLGF2F10
SCHEMBL13738443 0.79 PLAU (0.49) PLAUPLATPLGF2F10
SCHEMBL2242826 0.78 PLAU (0.58) PLAUPLATPLGF2F10
SCHEMBL2243330 0.77 PLAU (0.77) PLAUPLATPLGF2F10
SCHEMBL2246988 0.77 PLAU (0.59) PLAUPLATPLGF2F10
SCHEMBL2242322 0.77 F2 (0.39) PLAUPLATPLGF2F10
SCHEMBL2242623 0.76 PLAU (0.60) PLAUPLATPLGF2F10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8003627-B2 Urokinase inhibitors UNIVERSITEIT ANTWERPEN (BE) 2011-08-23 US disclosed
US-20080312191-A1 Novel Urokinase Inhibitors UNIVERSITEIT ANTWERPEN (BE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312191-A1 Novel Urokinase Inhibitors PLAU, PLAUR, SERPINE1 PLAU 1/4885PLAT 5/4885PLG 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.